tiprankstipranks
HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat
Market News

HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat

Story Highlights

Hims & Hers delivered robust numbers for the fourth quarter. The company remains optimistic about its future due to healthy demand for its offerings.

Hims & Hers (NYSE:HIMS) shares surged nearly 20% in the early session today after the telehealth platform’s fourth-quarter revenue jumped by 47.5% year-over-year to $246.6 million. Further, EPS of $0.01 exceeded estimates by $0.03.

Don't Miss our Black Friday Offers:

For the full year, revenue increased by 65% to $872 million. In Q4, the company’s subscriber base ballooned by 48% year-over-year to 1.5 million, and net orders rose by 24% to 2.3 million. However, its monthly online revenue per average subscriber moderated to $53 from $55 in the year-ago period.

Moreover, HIMS experienced robust double-digit growth across its Online and Wholesale verticals. This increase was accompanied by a robust 400 basis point expansion in the company’s gross margin.

For Fiscal Year 2024, HIMS expects revenue of $1.17 billion to $1.20 billion. Adjusted EBITDA for the year is anticipated in the range of $100 million to $120 million. For Q1, the company foresees revenue of $267 million to $272 million. Adjusted EBITDA for the quarter is seen landing between $22 million and $27 million. Notably, with demand for its personalized care solutions remaining buoyant, the company remains well on track to achieve its financial targets for 2025.

Is Hims & Hers a Good Stock to Buy?

Today’s price gains come on top of a nearly 50% rally in the company’s share price over the past six months. Overall, the Street has a Moderate Buy consensus rating on Hims & Hers alongside an average price target of $11.07. However, analysts’ views on the stock could change following its Q4 print.

Read full Disclosure

Related Articles
Vince CondarcuriHIMS Stock Surges after Court Case with Eli Lilly Gets Put on Hold
TipRanks Auto-Generated NewsdeskHims & Hers Health Expands Board with New Appointment
TheFlyFDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi
Go Ad-Free with Our App